GeoVax Labs, Inc., a clinical-stage biotechnology company, will present its cutting-edge research at the 37th Annual Roth Conference in Dana Point, California. Chairman and CEO David Dodd is scheduled to participate in a fireside chat on March 17, 2025, providing insights into the company’s pioneering work in vaccine development and cancer therapies.
The company’s lead clinical program, GEO-CM04S1, represents a next-generation COVID-19 vaccine currently undergoing multiple Phase 2 clinical trials. These trials are exploring the vaccine’s potential in critical patient populations, including immunocompromised individuals, patients with chronic lymphocytic leukemia, and as a booster for those previously vaccinated with mRNA vaccines.
Recently awarded a BARDA-funded contract, GeoVax will sponsor a comprehensive 10,000-participant Phase 2b clinical trial to evaluate GEO-CM04S1’s efficacy compared to existing COVID-19 vaccines. This research aims to address limitations in current vaccine technologies, particularly for patients with complex medical conditions.
In oncology, GeoVax is advancing Gedeptin®, an innovative oncolytic solid tumor gene-directed therapy. Having completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers, the company plans a Phase 2 clinical trial exploring Gedeptin® in combination with an immune checkpoint inhibitor for first recurrent head and neck cancer patients.
The company’s robust intellectual property portfolio and experienced leadership team position GeoVax at the forefront of developing transformative medical technologies targeting some of the world’s most challenging infectious diseases and cancer treatments.
This news story relied on a press release distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is GeoVax CEO to Present at 37th Annual Roth Conference, Highlighting COVID-19 Vaccine and Cancer Therapy Research.